©IDOSR PUBLICATIONS International Digital Organization for Scientific Research

IDOSR JOURNAL OF APPLIED SCIENCES 11(2):113-117, 2026 ISSN: 2550-7931

https://doi.org/10.59298/IDOSRJAS/2026/112113117 IDOSRJAS11200

CRISPR Cas9 Beta Cell Regeneration Therapy for Type 1 Diabetes: Mechanistic Insights and Clinical Translation

Mukisa Ian Mugaiga

Department of Pharmacology Kampala International University Uganda
Email:mugaiga.mukisa@studwc.kiu.ac.ug

ABSTRACT

Type 1 diabetes is a chronic autoimmune disorder characterized by immune-mediated destruction of pancreatic beta cells, resulting in lifelong dependence on exogenous insulin and risk of severe metabolic complications. Despite advances in insulin formulations and glucose monitoring technologies, current therapies failed to restore endogenous insulin production or fully prevent long term microvascular and macrovascular sequelae. CRISPR Cas9 genome editing emerged as a transformative platform capable of precise genetic modification, offering unprecedented opportunities for beta cell regeneration and immune modulation. The purpose of this review was to critically examine the mechanistic foundations and translational potential of CRISPR Cas9 based strategies for restoring functional beta cell mass in Type 1 diabetes. This article was developed through a comprehensive synthesis of peer reviewed literature integrating molecular immunology, beta cell biology, genome engineering technologies, and early translational studies. Evidence indicated that CRISPR mediated approaches may enable reprogramming of pancreatic cell lineages, enhancement of beta cell proliferation, correction of genetic susceptibility pathways, and engineering of immune evasive beta cells, while significant safety and regulatory challenges remain. CRISPR Cas9 driven beta cell regeneration represented a promising but complex therapeutic frontier that demands rigorous mechanistic validation and carefully designed clinical translation strategies.

Keywords: Type 1 diabetes; CRISPR Cas9, Beta cell regeneration, Genome editing, Translational endocrinology.

INTRODUCTION

Type 1 diabetes is an autoimmune endocrine disorder characterized by selective destruction of insulin-producing beta cells within the pancreatic islets of Langerhans [1, 2]. The disease commonly presents in childhood or adolescence and results in absolute insulin deficiency, chronic hyperglycemia, and increased risk of ketoacidosis, nephropathy, neuropathy, and cardiovascular disease [3, 4]. Although intensive insulin therapy and continuous glucose monitoring systems have substantially improved glycemic control, these approaches do not restore endogenous glucose-responsive insulin secretion and remain associated with hypoglycemia risk and long-term complications [5].

The pathogenesis of Type 1 diabetes involves genetic susceptibility, environmental triggers, and dysregulated immune responses that culminate in autoreactive T cell-mediated beta cell destruction [6]. Current immunomodulatory interventions provide only transient preservation of residual beta cell function and are limited by systemic effects. Islet transplantation demonstrates proof of principle for cell replacement therapy but is constrained by donor scarcity, immune rejection, and lifelong immunosuppression [7].

Advances in genome editing technologies, particularly CRISPR Cas9, have created new possibilities for targeted genetic modification and regenerative medicine [8]. By enabling precise alteration of genomic sequences, CRISPR-based strategies offer the potential to regenerate functional beta cells, reprogram alternative pancreatic cell types, and engineer immune-resistant cellular grafts. Such approaches may address both the loss of beta cell mass and the underlying autoimmune pathology [9]. This review examines the molecular mechanisms of beta cell destruction, the principles of CRISPR Cas9 genome editing, emerging strategies for CRISPR-mediated beta cell regeneration, immunological and safety considerations, and the translational pathway toward clinical application. The purpose of this article is to provide a mechanistically grounded and clinically informed evaluation of CRISPR Cas9 based beta cell regeneration therapy as a transformative approach for Type 1 diabetes.

Molecular Pathogenesis of Type 1 Diabetes and Beta Cell Loss

Type 1 diabetes arises from a complex interplay between genetic predisposition and immune dysregulation. Susceptibility is strongly associated with specific human leukocyte antigen class II alleles, particularly HLA DR and DQ haplotypes, which influence antigen presentation and T cell activation [10]. Additional loci, including INS, PTPN22, and CTLA4, contribute to immune tolerance defects and altered beta cell vulnerability.

The hallmark of disease progression is infiltration of pancreatic islets by autoreactive CD4 and CD8 T lymphocytes, macrophages, and dendritic cells, a process termed insulitis [11]. Proinflammatory cytokines such as interleukin 1 beta, interferon gamma, and tumor necrosis factor alpha induce oxidative stress, endoplasmic reticulum stress, and activation of intrinsic apoptotic pathways within beta cells. Nuclear factor kappa B signaling and mitochondrial dysfunction further amplify beta cell demise.

Beta cells exhibit limited intrinsic regenerative capacity in humans. Although transient proliferation can occur during early life, chronic inflammatory stress suppresses cell cycle progression and promotes senescence. Furthermore, immune-mediated destruction persists even if beta cell mass is partially restored, creating a hostile microenvironment that impedes endogenous regeneration [12]. Understanding these molecular mechanisms is essential for designing CRISPR-based interventions aimed at both restoring beta cell mass and modifying immune pathways that perpetuate destruction.

CRISPR Cas9 Genome Editing: Molecular Mechanisms and Engineering Platforms

CRISPR Cas9 is derived from an adaptive bacterial immune system that utilizes RNA-guided nucleases to target specific DNA sequences [13]. In therapeutic applications, a single-guide RNA directs the Cas9 endonuclease to a complementary genomic locus adjacent to a protospacer adjacent motif [14]. Cas9 induces a double-strand break, which is subsequently repaired by endogenous cellular mechanisms.

Non-homologous end joining introduces insertions or deletions that may disrupt gene function. Homology-directed repair enables precise sequence correction when a donor template is provided, although its efficiency is lower in non-dividing cells. Recent innovations, including base editing and prime editing, permit targeted nucleotide conversions without inducing double-strand breaks, thereby reducing genomic instability.

Efficient delivery of CRISPR components remains a central challenge. Viral vectors such as adeno-associated virus provide high transduction efficiency but are limited by packaging capacity and potential immunogenicity [15]. Non-viral systems, including lipid nanoparticles and electroporation of ribonucleoprotein complexes, offer transient expression and reduced off-target risk. A nuanced understanding of editing efficiency, specificity, and cellular context is required to translate CRISPR technologies into safe regenerative therapies for endocrine disorders.

Strategies for CRISPR-Mediated Beta Cell Regeneration

CRISPR-based beta cell regeneration strategies may be broadly categorized into lineage reprogramming, enhancement of proliferation, and engineering of stem cell-derived beta cells [16-20]. One promising approach involves reprogramming pancreatic alpha cells or ductal cells into insulin-producing beta-like cells through activation of key transcription factors such as PDX1, MAFA, and NGN3. Targeted editing can modulate epigenetic regulators that constrain lineage plasticity, thereby promoting trans differentiation.

Alternatively, CRISPR-mediated activation of cell cycle regulators, including cyclin-dependent kinases, may enhance proliferation of residual beta cells [17,21-24]. Precise modulation is essential to avoid uncontrolled growth or oncogenic transformation. Editing of stress response genes may also improve beta cell resilience under inflammatory conditions.

Stem cell-derived beta cells represent another transformative avenue. Human pluripotent stem cells can be differentiated into insulin-secreting cells in vitro, followed by CRISPR-based modification to enhance glucose responsiveness or confer immune evasion through alteration of major histocompatibility complex expression [18,25-30]. Correction of susceptibility genes in autologous induced pluripotent stem cells further expands personalized

therapeutic potential. Collectively, these strategies aim to restore functional beta cell mass while addressing intrinsic and extrinsic barriers to regeneration.

Immunological Considerations and Safety Challenges

Regeneration of beta cells alone is insufficient if autoimmune destruction persists. Recurrent immune attack represents a major obstacle to durable therapeutic success. CRISPR technology may be leveraged to edit immune checkpoints or engineer beta cells with reduced antigen presentation capacity, thereby diminishing recognition by autoreactive T cells [19]. However, immune evasion strategies must be balanced against the risk of impaired immune surveillance. Off-target genome editing remains a critical concern, as unintended mutations may disrupt tumor suppressor genes or activate oncogenic pathways [20]. High-fidelity Cas9 variants and rigorous genomic screening are essential to minimize these risks.

Immunogenicity of the Cas9 protein itself may provoke adaptive immune responses, particularly in individuals previously exposed to bacterial species from which Cas9 is derived. Transient delivery systems and alternative nucleases may mitigate this challenge.

Long-term monitoring for genomic instability, insertional mutagenesis, and ectopic tissue formation will be necessary in clinical trials. Ethical considerations surrounding germline editing must be clearly distinguished from somatic therapeutic applications.

Translational and Clinical Development Pathways

Preclinical models, including non obese diabetic mice and humanized immune system models, provide platforms for evaluating efficacy and safety of CRISPR-mediated beta cell regeneration [21, 22]. Early studies demonstrate improved glycemic control following transplantation of engineered beta-like cells, although durability remains under investigation.

Clinical translation will require scalable manufacturing of edited cells under good manufacturing practice conditions. Standardization of differentiation protocols, genomic validation assays, and quality control metrics is imperative. Regulatory agencies will demand comprehensive assessment of off-target effects, tumorigenic potential, and long-term functional stability.

Early phase clinical trials should prioritize safety endpoints while assessing restoration of endogenous insulin secretion and reduction in exogenous insulin requirements. Combination strategies integrating immune modulation with regenerative editing may enhance therapeutic durability [23].

Ethical considerations include equitable access, informed consent, and responsible communication of therapeutic expectations [24]. Multidisciplinary collaboration among molecular biologists, endocrinologists, immunologists, and regulatory experts will be essential to navigate this complex translational landscape.

CONCLUSION

CRISPR Cas9-based beta cell regeneration therapy represents a paradigm shift in the management of Type 1 diabetes by directly addressing the fundamental loss of insulin-producing cells. Mechanistic insights into autoimmune beta cell destruction, coupled with advances in genome editing precision, provide a rational foundation for regenerative intervention. Strategies encompassing lineage reprogramming, proliferation enhancement, stem cell engineering, and immune modulation illustrate the breadth of therapeutic possibilities. Nonetheless, significant challenges persist, including autoimmune recurrence, off-target editing risks, immunogenicity of editing components, and regulatory complexity. Durable clinical success will depend on harmonizing precise genomic modification with effective immune protection and long-term safety monitoring. The convergence of molecular endocrinology, genome engineering, and translational medicine offers unprecedented potential to move beyond symptomatic treatment toward disease modification. Rigorous mechanistic research integrated with carefully designed early-phase clinical trials should be prioritized to establish the safety, durability, and immunological compatibility of CRISPR Cas9-mediated beta cell regeneration therapy for Type 1 diabetes.

REFERENCES

1. Roep, B.O., Thomaidou, S., van Tienhoven, R., Zaldumbide, A.: Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol. 17, 150–161 (2021). https://doi.org/10.1038/s41574-020-00443-4
2. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Natural Product Communications. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
3. Chiang, J.L., Maahs, D.M., Garvey, K.C., Hood, K.K., Laffel, L.M., Weinzimer, S.A., Wolfsdorf, J.I., Schatz, D.: Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association. Diabetes Care. 41, 2026–2044 (2018). https://doi.org/10.2337/dci18-0023

4. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
5. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obesity Medicine. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
6. Tang, Y., Wang, W., Huang, Z., Zhang, C., Zhang, J., Pang, Y., Li, S.: Environmental Mechanisms Influencing the Pathogenesis and Progression of Type 1 Diabetes. International Journal of Molecular Sciences. 26, (2025). https://doi.org/10.3390/ijms262311613
7. Wang, X., Zeng, Z., Li, D., Wang, K., Zhang, W., Yu, Y., Wang, X.: Advancements and Challenges in Immune Protection Strategies for Islet Transplantation. Journal of Diabetes. 17, e70048 (2025). https://doi.org/10.1111/1753-0407.70048
8. Aljabali, A.A.A., El-Tanani, M., Tambuwala, M.M.: Principles of CRISPR-Cas9 technology: Advancements in genome editing and emerging trends in drug delivery. Journal of Drug Delivery Science and Technology. 92, 105338 (2024). https://doi.org/10.1016/j.jddst.2024.105338
9. Aja, P.M., Agu, P.C., Ogbu, C., Alum, E.U., Fasogbon, I.V., Musyoka, A.M., Ngwueche, W., Egwu, C.O., Tusubira, D., Ross, K.: RNA research for drug discovery: Recent advances and critical insight. Gene. 947, 149342 (2025). https://doi.org/10.1016/j.gene.2025.149342
10. McAulay, K.A., Jarrett, R.F.: Human leukocyte antigens and genetic susceptibility to lymphoma. Tissue Antigens. 86, 98–113 (2015). https://doi.org/10.1111/tan.12604
11. Cosentino, C., Regazzi, R.: Crosstalk between Macrophages and Pancreatic β-Cells in Islet Development, Homeostasis and Disease. International Journal of Molecular Sciences. 22, (2021). https://doi.org/10.3390/ijms22041765
12. Zhong, F., Jiang, Y.: Endogenous Pancreatic β Cell Regeneration: A Potential Strategy for the Recovery of β Cell Deficiency in Diabetes. Front. Endocrinol. 10, (2019). https://doi.org/10.3389/fendo.2019.00101
13. Ikpozu, E.N., Offor, C.E., Igwenyi, I.O., Obaroh, I.O., Ibiam, U.A., Ukaidi, C.U.A.: RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diabetes & Vascular Disease Research. 22, 14791641251334726 (2025). https://doi.org/10.1177/14791641251334726
14. Farboud, B., Meyer, B.J.: Dramatic Enhancement of Genome Editing by CRISPR/Cas9 Through Improved Guide RNA Design. Genetics. 199, 959–971 (2015). https://doi.org/10.1534/genetics.115.175166
15. Li, C., Samulski, R.J.: Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 21, 255–272 (2020). https://doi.org/10.1038/s41576-019-0205-4
16. Abdalla, M.M.I.: Advancing diabetes management: Exploring pancreatic beta-cell restoration's potential and challenges. World J Gastroenterol. 30, 4339–4353 (2024). https://doi.org/10.3748/wjg.v30.i40.4339
17. Ford, K., Munson, B.P., Fong, S.H., Panwala, R., Chu, W.K., Rainaldi, J., Plongthongkum, N., Arunachalam, V., Kostrowicki, J., Meluzzi, D., Kreisberg, J.F., Jensen-Pergakes, K., VanArsdale, T., Paul, T., Tamayo, P., Zhang, K., Bienkowska, J., Mali, P., Ideker, T.: Multimodal perturbation analyses of cyclin-dependent kinases reveal a network of synthetic lethalities associated with cell-cycle regulation and transcriptional regulation. Sci Rep. 13, 7678 (2023). https://doi.org/10.1038/s41598-023-33329-2
18. Balboa Alonso, D.: Human pluripotent stem cells and CRISPR-Cas9 genome editing to model diabetes. Helsingin yliopisto, Helsinki (2018)
19. Karaoglu, I.C., Duymaz, D., Rashid, M.M., Kizilel, S.: Immune-evasive beta cells in type 1 diabetes: innovations in genetic engineering, biomaterials, and computational modeling. Front. Immunol. 16, (2025). https://doi.org/10.3389/fimmu.2025.1618086
20. Acosta, J., Wang, W., Feldser, D.M.: Off and back-on again: a tumor suppressor's tale. Oncogene. 37, 3058–3069 (2018). https://doi.org/10.1038/s41388-018-0186-3
21. Abdalla, M.M.I.: Advancing diabetes management: Exploring pancreatic beta-cell restoration's potential and challenges. World J Gastroenterol. 30, 4339–4353 (2024). https://doi.org/10.3748/wjg.v30.i40.4339
22. Karaoglu, I.C., Duymaz, D., Rashid, M.M., Kizilel, S.: Immune-evasive beta cells in type 1 diabetes: innovations in genetic engineering, biomaterials, and computational modeling. Front. Immunol. 16, (2025). https://doi.org/10.3389/fimmu.2025.1618086
23. Youssef, E., Fletcher, B., Palmer, D.: Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology. Front. Med. 11, (2025). https://doi.org/10.3389/fmed.2024.1527600

24. Ekpang II, J.E., Ekpang, P.O., Ainebyoona, C., Nwagu, K.E., Nwuruku, O.A., Muhammad, K.: Toward an ethical future for orphan drugs: balancing access, affordability, and innovation. Journal of Medical Economics. 0, 1–24. https://doi.org/10.1080/13696998.2025.2577514
25. Ugwu OPC, Okon MB, Ogenyi FC, Ugwu CN, Ugwu JN. Self-amplifying RNA (saRNA) and circular RNA (circRNA) vaccines: progress, evidence gaps, and translational pathways for durable and scalable immunization. Hum Vaccin Immunother. 2026;22(1):2661120.
26. Ugwu OPC, Okon MB, Ogenyi FC, Ugwu CN, Ugwu JN. Circular RNA therapeutics: a new class of long-acting RNA medicines for oncology, immunology, and rare diseases. Front Immunol. 2026;17:1758902.
27. Ugwu OPC, Ogenyi FC, Basajja M, Ugwu CN, Okon MB. Nanoparticle-mediated mRNA delivery for cancer, autoimmunity, and genetic diseases: a rapid review. Front Drug Deliv. 2026;6:1793322.
28. Okon MB, Ugwu OPC, Ugwu CN, Ogenyi FC, Swase DT, Anyanwu CN, et al. From pandemics to preparedness: harnessing AI, CRISPR, and synthetic biology to counter biosecurity threats. Front Public Health. 2025;13:1711344.
29. Okon MB, Olorunnisola SO, Ifie JE, Ugwu OPC, Alum EU. Transgenerational reproductive risks of BPA: epigenetic mechanisms and biomarker applications. A critical review. Environ Epigenet. 2026:dvag010.
30. Okon MB, Ugwu OPC, Ugwu CN, Ogenyi FC, Swase DT, Alum EU, et al. Endocrine disruption rewards: bisphenol-A-induced reproductive toxicity and the precision ameliorative potential of flavonoids in preclinical studies. A systematic review and meta-analysis. Front Toxicol. 2025;7:1687862.

CITE AS: Mukisa Ian Mugaiga (2026). CRISPR Cas9 Beta Cell Regeneration Therapy for Type 1 Diabetes: Mechanistic Insights and Clinical Translation. IDOSR JOURNAL OF APPLIED SCIENCES 11(2):113-117. https://doi.org/10.59298/IDOSRJAS/2026/112113117